Combating Susceptibility to Drug Resistance: Lessons from HIV-1 Protease
- 31 October 2004
- journal article
- research article
- Published by Elsevier in Chemistry & Biology
- Vol. 11 (10), 1333-1338
- https://doi.org/10.1016/j.chembiol.2004.08.010
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral TherapyJournal of Virology, 2003
- In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug ExposureJournal of Clinical Microbiology, 2001
- Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease InhibitorsAIDS Research and Human Retroviruses, 2000
- How does a symmetric dimer recognize an asymmetric substrate? a substrate complex of HIV-1 proteaseJournal of Molecular Biology, 2000
- Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 ProteaseJournal of Medicinal Chemistry, 1997
- The not-so-great escapeNature Structural & Molecular Biology, 1995
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- Fidelity of HIV-1 reverse transcriptase copying RNA in vitroBiochemistry, 1992
- Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostereJournal of Medicinal Chemistry, 1991
- The MIDAS display systemJournal of Molecular Graphics, 1988